0001213900-24-060093.txt : 20240709 0001213900-24-060093.hdr.sgml : 20240709 20240709153722 ACCESSION NUMBER: 0001213900-24-060093 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240709 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240709 DATE AS OF CHANGE: 20240709 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 60 DEGREES PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001946563 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 452406880 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41719 FILM NUMBER: 241107401 BUSINESS ADDRESS: STREET 1: 1025 CONNECTICUT AVENUE NW STREET 2: SUITE 1000 CITY: WASHINGTON STATE: DC ZIP: 20036 BUSINESS PHONE: 202-327-5422 MAIL ADDRESS: STREET 1: 1025 CONNECTICUT AVENUE NW STREET 2: SUITE 1000 CITY: WASHINGTON STATE: DC ZIP: 20036 8-K 1 ea0209161-8k_60degrees.htm CURRENT REPORT
false 0001946563 DC 0001946563 2024-07-09 2024-07-09 0001946563 SXTP:CommonStockParValue0.0001Member 2024-07-09 2024-07-09 0001946563 SXTP:WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember 2024-07-09 2024-07-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): July 9, 2024

 

60 DEGREES PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41719   45-2406880
(State or other jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification Number)

 

1025 Connecticut Avenue NW, Suite 1000
Washington, D.C.		   20036
(Address of registrant’s principal executive office)   (Zip code)

 

(202) 327-5422

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001   SXTP   The Nasdaq Stock Market LLC
Warrants, each warrant to purchase one share of Common Stock   SXTPW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events.

 

On July 9, 2024, 60 Degrees Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it enrolled its first patient in its clinical trial of tafenoquine for Babesiosis at Tufts Medical Center, which is the first and only study of its kind. The Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The goal of the study is to confirm the findings of an 80 percent babesiosis cure rate in humans observed in a similar population in an earlier case series of tafenoquine completed by Yale School of Public Health (YSPH) in April 2024 and published in the journal, Clinical Infectious Diseases. The YSPH case series showed a cure rate (with a 95 percent confidence interval) of 80 percent (30-100 percent) in a series of five immunosuppressed patients who were administered weekly tafenoquine following a loading dose in combination with standard of care medications.

 

Forward-Looking Statements

 

This Item 8.01 of this Current Report on Form 8-K contains “forward-looking statements.” Such statements which are not purely historical (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “intends,” “would,” “could” and “estimates”) are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, regulatory milestones.

 

Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this Form 8-K, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this Form 8-K are reasonable, there can be no assurance that such goals, beliefs, plans, expectations or intentions will prove to be accurate, including but not limited to the results of the study described in this Item 8.01. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the Company’s reports and statements filed from time-to-time with the Securities and Exchange Commission.

 

The information set forth under this Item 8.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibits are being filed herewith:

 

Exhibit No.   Description
99.1   Press Release of 60 Degrees Pharmaceuticals, Inc. dated as of July 9, 2024.
104     Cover Page Interactive Data File (embedded with the Inline XBRL document).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  60 DEGREES PHARMACEUTICALS, INC.
     
Date: July 9, 2024 By: /s/ Geoffrey Dow
  Name: Geoffrey Dow
  Title: Chief Executive Officer and President

 

2

 

 EX-99.1 2 ea020916101ex99-1_60degrees.htm PRESS RELEASE OF 60 DEGREES PHARMACEUTICALS, INC. DATED AS OF JULY 9, 2024

Exhibit 99.1

 

 

 

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

 

WASHINGTON, D.C., July 9, 2024 -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced ethics approval of an open label, expanded access study of the ARAKODA® regimen of tafenoquine in combination with standard of care regimens in immunosuppressed patients with persistent/relapsing babesiosis.

 

The goal of the study is to confirm the findings of an 80 percent babesiosis cure rate in humans observed in a similar population in an earlier case series of tafenoquine completed by Yale School of Public Health (YSPH) in April 2024 and published in the journal, Clinical Infectious Diseases. The YSPH case series showed a cure rate (with a 95 percent confidence interval) of 80 percent (30-100 percent) in a series of five immunosuppressed patients who were administered weekly tafenoquine following a loading dose in combination with standard of care medications.

 

Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA. Tafenoquine has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the U.S. Food and Drug Administration (FDA) for such an indication.

 

Babesiosis is a tick-borne illness caused by Babesia parasites that develop and multiply in red blood cells. Its symptoms include fevers, chills, sweats, and fatigue, and in severe cases, can be life-threatening. Incidence of the disease is rapidly rising, particularly in the Northeast. Transmitted through the bite of the black-legged (deer) tick, the vector that spreads Lyme disease, babesiosis is an orphan disease. It may be life-threatening in elderly and immunosuppressed patients.

 

“Tafenoquine is showing exciting promise in addressing babesiosis within various human patient populations,” said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoffrey Dow, PhD. “With babesiosis rates now rising in key regions of the United States and given the very serious nature of this tick-borne illness, especially in the elderly and immunocompromised people, we are moving quickly in an effort to confirm Yale’s observations while advancing the clinical program for hospitalized babesiosis patients which is now enrolling at Tufts Medical Center. Ultimately, we aim to re-purpose tafenoquine as a new babesiosis treatment.”

 

Sometimes called “compassionate use,” expanded access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy option is available.

 

 

 

 

About the 60 Degrees Pharmaceuticals Program for Tafenoquine in Babesiosis

 

60 Degrees Pharmaceuticals is engaged in advancing multiple clinical trials to establish the safety and efficacy of tafenoquine. They are the: 1.) study of hospitalized (i.e., acute) babesiosis patients, now enrolling at Tufts Medical Center; 2.) expanded access for Tafenoquine in Babesiosis trial intended to confirm recent findings by Yale School of Public Health; and 3.) expanded access study being planned for chronic babesiosis, the design of which will be gated by an ongoing epidemiological study at North Carolina State College of Veterinary Medicine assessing whether Babesia spp parasites are present in samples from human patients who have chronic fatigue/neurologic symptoms.

 

The three studies address unmet medical need in three important populations of human babesiosis patients: (i) patients hospitalized with severe disease; (ii) patients with persistent disease who have risk factors for relapse; and (iii) individuals with a diagnosis of chronic babesiosis based on clinical manifestations and prior medical history. Based on eventual data from all three trials, 60 Degrees Pharmaceuticals plans to file a New Drug Application with the FDA in the second quarter of 2026 for a supplemental indication for tafenoquine in babesiosis.

 

The Company believes that the total accessible market through the end of patent protection in December 2035 in the U.S. for ARAKODA (tafenoquine) for babesiosis is 38,000 (hospitalized and immunosuppressed) acute patients and at least 375,000 patients with chronic babesiosis. The prevalence of patients with chronic disease may be higher and is the subject of ongoing market research and epidemiological studies being conducted by the Company. This is in addition to the potential 1.7 million travelers who could benefit from the use of ARAKODA for malaria prophylaxis over the same period.

 

Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA®. The safety of the approved regimen of tafenoquine for malaria prophylaxis has been assessed in five separate randomized, double-blind, active comparator or placebo-controlled trials for durations of up to six months. Tafenoquine has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the FDA for such an indication.

 

About ARAKODA® (tafenoquine)

 

Tafenoquine was discovered by Walter Reed Army Institute of Research with funding from the United States Army Medical Materiel Development Activity. Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only malaria prevention drug.

 

2

 

 

About 60 Degrees Pharmaceuticals, Inc.

 

60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com.

 

The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. The statements expressed herein are those of 60 Degrees Pharmaceuticals, Inc. and do not necessarily represent those of the U.S. Department of Defense.

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

 

###

 

Media Contact:

 

Sheila A. Burke

SheilaBurke-consultant@60degreespharma.com

(484) 667-6330

 

Investor Contact:

 

Patrick Gaynes

patrickgaynes@60degreespharma.com

(310) 989-5666

 

3

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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sxtp-20240709.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 sxtp-20240709_def.xml XBRL DEFINITION FILE EX-101.LAB 6 sxtp-20240709_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, par value $0.0001 Warrants, each warrant to purchase one share of Common Stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 sxtp-20240709_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Cover
Jul. 09, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 09, 2024
Entity File Number 001-41719
Entity Registrant Name 60 DEGREES PHARMACEUTICALS, INC.
Entity Central Index Key 0001946563
Entity Tax Identification Number 45-2406880
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1025 Connecticut Avenue NW, Suite 1000
Entity Address, City or Town Washington
Entity Address, State or Province DC
Entity Address, Postal Zip Code 20036
City Area Code 202
Local Phone Number 327-5422
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Stock, par value $0.0001  
Title of 12(b) Security Common Stock, par value $0.0001
Trading Symbol SXTP
Security Exchange Name NASDAQ
Warrants, each warrant to purchase one share of Common Stock  
Title of 12(b) Security Warrants, each warrant to purchase one share of Common Stock
Trading Symbol SXTPW
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 3 23 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://60degreespharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea0209161-8k_60degrees.htm sxtp-20240709.xsd sxtp-20240709_def.xml sxtp-20240709_lab.xml sxtp-20240709_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0209161-8k_60degrees.htm": { "nsprefix": "SXTP", "nsuri": "http://60degreespharma.com/20240709", "dts": { "inline": { "local": [ "ea0209161-8k_60degrees.htm" ] }, "schema": { "local": [ "sxtp-20240709.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "definitionLink": { "local": [ "sxtp-20240709_def.xml" ] }, "labelLink": { "local": [ "sxtp-20240709_lab.xml" ] }, "presentationLink": { "local": [ "sxtp-20240709_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 26 }, "report": { "R1": { "role": "http://60degreespharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-07-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0209161-8k_60degrees.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-07-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0209161-8k_60degrees.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://60degreespharma.com/role/Cover" ], "auth_ref": [] }, "SXTP_CommonStockParValue0.0001Member": { "xbrltype": "domainItemType", "nsuri": "http://60degreespharma.com/20240709", "localname": "CommonStockParValue0.0001Member", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock, par value $0.0001" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "SXTP_WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://60degreespharma.com/20240709", "localname": "WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrants, each warrant to purchase one share of Common Stock" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://60degreespharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 18 0001213900-24-060093-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-060093-xbrl.zip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end XML 19 ea0209161-8k_60degrees_htm.xml IDEA: XBRL DOCUMENT 0001946563 2024-07-09 2024-07-09 0001946563 SXTP:CommonStockParValue0.0001Member 2024-07-09 2024-07-09 0001946563 SXTP:WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember 2024-07-09 2024-07-09 iso4217:USD shares iso4217:USD shares false 0001946563 DC 8-K 2024-07-09 60 DEGREES PHARMACEUTICALS, INC. DE 001-41719 45-2406880 1025 Connecticut Avenue NW, Suite 1000 Washington 20036 202 327-5422 false false false false Common Stock, par value $0.0001 SXTP NASDAQ Warrants, each warrant to purchase one share of Common Stock SXTPW NASDAQ true false